1 option
Clinical review report : indication: multiple sclerosis, relapsing-remitting. Ofatumumab (Kesimpta) (Novartis Pharmaceuticals Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Outcome assessment (Medical care).
- Outcome assessment (Medical care)--Methodology.
- Physical Description:
- 1 online resource
- Edition:
- Final (with redactions).
- Place of Publication:
- Ottawa, ON : Canadian Agency for Drugs and Technologies in Health, 2021.
- Summary:
- The current drug under review, ofatumumab (20 mg/0.4 mL), is indicated for the treatment of adult patients with RRMS with active disease defined by clinical and imaging features. Ofatumumab is a human monoclonal antibody (immunoglobulin G1) that is available as a solution for subcutaneous injection. The recommended dose is 20 mg, to be initially administered weekly at weeks 0 (beginning of treatment), 1, and 2, followed by monthly dosing starting at week 4. The sponsor has requested reimbursement of ofatumumab as per the indication under review.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.